Publication Name	World Journal of Clinical Oncology
Manuscript ID	89001
Country	China

Received	2023-10-17 15:50
Peer-Review Started	2023-10-17 15:51
First Decision by Editorial Office Director	2023-12-31 07:04
Return for Revision	2023-12-31 07:04
Revised	2024-01-14 03:34
Publication Fee Transferred
Second Decision by Editor	2024-02-03 02:45
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-02-03 05:25
Articles in Press	2024-02-03 05:25
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-14 03:32
Publish the Manuscript Online	2024-03-22 11:48

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Jin-Yu Shi, Xin Che, Rui Wen, Si-Jia Hou, Yu-Jia Xi, Yi-Qian Feng, Ling-Xiao Wang, Shi-Jia Liu, Wen-Hao Lv and Ya-Fen Zhang
ORCID	Author(s) ORCID Number Ya-Fen Zhang http://orcid.org/0009-0003-6058-1177
Funding Agency and Grant Number	Funding Agency Grant Number The Science and Technology Commission of Shanxi province 201901D111428
Corresponding Author	Ya-Fen Zhang, MD, Chief Doctor, Department of Breast Surgery, The Fifth Hospital of Shanxi Medical University, Shuangta West Street, Yingze District, Taiyuan 030000, Shanxi Province, China. cocoren2005@163.com
Key Words	HER2+ breast cancer; Ferroptosis; Tumor mutation burden; Single-cell RNA sequencing; Prognosis
Core Tip	A prognostic model constructed with four ferroptosis-related genes (PROM2, SLC7A11, FANCD2, and FH) combined with tumor mutation burden can be used to evaluate the prognosis of patients with HER2-positive breast cancer more accurately.
Publish Date	2024-03-22 11:48
Citation	Shi JY, Che X, Wen R, Hou SJ, Xi YJ, Feng YQ, Wang LX, Liu SJ, Lv WH, Zhang YF. Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer. World J Clin Oncol 2024; 15(3): 391-410
URL	https://www.wjgnet.com/2218-4333/full/v15/i3/391.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i3.391

Full Article (PDF)	WJCO-15-391-with-cover.pdf
Manuscript File	89001_Auto_Edited-YJP.docx
Answering Reviewers	89001-Answering reviewers.pdf
Audio Core Tip	89001-Audio core tip.mp3
Biostatistics Review Certificate	89001-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	89001-Conflict-of-interest statement.pdf
Copyright License Agreement	89001-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	89001-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	89001-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	89001-Language certificate.pdf
Supplementary Material	89001-Supplementary material.pdf
Peer-review Report	89001-Peer-review(s).pdf
Scientific Misconduct Check	89001-Bing-Li L-2.png
Scientific Editor Work List	89001-Scientific editor work list.pdf
CrossCheck Report	89001-CrossCheck report.pdf
CrossCheck Report	89001-CrossCheck.png